BUSINESS SITUATION
The client, a biotechnology company focused on developing new therapies to address the medical needs of patients with chronic illnesses, wanted to track key competitor activities for marketed and pipeline molecules in PAH.
SGA APPROACH
- SGA gathered information from a diverse range of sources, including paid databases and publicly available resources, such as company press releases, financial documents, investor presentations, and corporate reports.
- SGA conducted a comprehensive study to gain insights into the FDA-approved drugs, generics, and market share of the key brands.
- To establish a competitive clinical pipeline, SGA performed extensive secondary research by utilizing various clinical trial registries, company pipeline data, publications, and SEC filings.
- To get news on time, SGA used Google alerts, RSS feeds, company subscriptions, and an in-house web scrapping tool.
- SGA also covered the key conferences in the PAH space like ATS (American Thoracic Society), World Symposium on Pulmonary Hypertension, American College of Chest Physicians (CHEST), American Heart Association (AHA), and European Society of Cardiology (ESC)
ENGAGEMENT
SGA engaged with the Head of Competitive Intelligence based in the US. SGA actively collaborated with the client throughout the process to support the R&D and commercialization strategy.
BENEFITS & OUTCOME
- SGA delivered insights in the form of daily newsletters and monthly reports
- Utilizing SGA insights, the client managed to continuously refine its commercialization strategy, enhancing competitiveness in the marketplace
KEY TAKEAWAYS
- Prompt diagnosis and treatment are essential for PAH optimal management
- Current vasodilator therapies, although successful in alleviating symptoms, do not address the fundamental cellular proliferation responsible for disease progression
- Late-stage pipeline is driven by Platelet-derived growth factors (PDGF) inhibitors
